Abionyx Pharma (LTS:0RAG) EV-to-EBIT : -11.28 (As of Jun. 05, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Abionyx Pharma EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Abionyx Pharma's Enterprise Value is €39.48 Mil. Abionyx Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-3.50 Mil. Therefore, Abionyx Pharma's EV-to-EBIT for today is -11.28.

The historical rank and industry rank for Abionyx Pharma's EV-to-EBIT or its related term are showing as below:

LTS:0RAG' s EV-to-EBIT Range Over the Past 10 Years
Min: -16.42 Med: -2.82 Max: 0.29
Current: -11.28

During the past 11 years, the highest EV-to-EBIT of Abionyx Pharma was 0.29. The lowest was -16.42. And the median was -2.82.

LTS:0RAG's EV-to-EBIT is ranked worse than
100% of 425 companies
in the Biotechnology industry
Industry Median: 9.61 vs LTS:0RAG: -11.28

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Abionyx Pharma's Enterprise Value for the quarter that ended in Dec. 2023 was €40.23 Mil. Abionyx Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-3.50 Mil. Abionyx Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -8.70%.

Abionyx Pharma EV-to-EBIT Historical Data

The historical data trend for Abionyx Pharma's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abionyx Pharma EV-to-EBIT Chart

Abionyx Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

0.09

-7.95

-11.14

-11.67

-11.65

Abionyx Pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															-11.14	-	-11.67	-	-11.65

Competitive Comparison of Abionyx Pharma's EV-to-EBIT

For the Biotechnology subindustry, Abionyx Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abionyx Pharma's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abionyx Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Abionyx Pharma's EV-to-EBIT falls into.

Abionyx Pharma EV-to-EBIT Calculation

Abionyx Pharma's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	39.475	/	-3.499
	=	-11.28

Abionyx Pharma's current Enterprise Value is €39.48 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Abionyx Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-3.50 Mil.

Abionyx Pharma (LTS:0RAG) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Abionyx Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-3.499	/	40.2337152
	=	-8.70 %

Abionyx Pharma's Enterprise Value for the quarter that ended in Dec. 2023 was €40.23 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Abionyx Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-3.50 Mil.

Abionyx Pharma EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Abionyx Pharma's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Abionyx Pharma (LTS:0RAG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abionyx Pharma (LTS:0RAG) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

ABNX:France 609:Germany

Address

33-43 Avenue Georges Pompidou-Bat D2, Balma, FRA, 31130

Website

https://www.abionyx.com

Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.

Abionyx Pharma (LTS:0RAG) Headlines

No Headlines